Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Follistatin 344 cycle length: what human studies ran

Not approved — research use only
Short answer: there is no established Follistatin 344 cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Follistatin 344 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Follistatin 344 cycle length?
No. We found no human studies that report a treatment duration for Follistatin 344.
What is the longest human study of Follistatin 344?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Follistatin 344 dosing reference Full research page

References

  1. Regulation of myostatin activity and muscle growth Proceedings of the National Academy of Sciences. 2001
  2. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease Muscle & Nerve. 2009
  3. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy Molecular Therapy. 2015
  4. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes Molecular Therapy. 2017
  5. Phase I Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis (NCT01519349, completed October 2017, 15 participants) ClinicalTrials.gov. 2017
  6. Phase I/II Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy (NCT02354781, completed November 2017, 3 participants) ClinicalTrials.gov. 2017
  7. CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy (NCT07443826, phase 1/2, recruiting, estimated 12 participants) ClinicalTrials.gov. 2026
  8. Detection of black market follistatin 344 (erratum: Drug Test Anal 2020;12:1522-1533) Drug Testing and Analysis. 2019
  9. Erratum: Detection of black market follistatin 344 Drug Testing and Analysis. 2020
  10. World Anti-Doping Code International Standard Prohibited List 2026 WADA. 2026
  11. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  12. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Sports Medicine. 2026